Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

Conditions:   Hepatic Veno-Occlusive Disease;   Nephroblastoma;   Acute Lymphoblastic Leukemia Intervention:   Other: Blood test for genetic analysis Sponsor:   University Hospital, Angers Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 11 December 2019Source: The Lancet HaematologyAuthor(s): Xavier Thomas
Source: The Lancet Haematology - Category: Hematology Source Type: research
This study is registered with Clinicaltrials.gov, number NCT02560025, and has completed enrolment.FindingsBetween Dec 31, 2015, and Aug 1, 2017, we enrolled a total of 39 eligible patients. 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. At mid-induction, 33 (85%) of 39 patients showed marrow aplasia, six (15%) received re-induction. The median follow-up was 13·7 months (IQR 12·7–14·4). Composite remission was 64% (two-stage 95% CI 48–79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achiev...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Condition:   Acute Lymphoblastic Leukemia ,Lymphomas Intervention:   Biological: Anti-CD19 CAR-T Sponsor:   The First Affiliated Hospital of Nanchang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Myeloid Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Granulocyte Colony-Stimulating Factor;   Drug: Mitoxantrone Sponsors:   University of Washington;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Myeloid Neoplasm Interventions:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Drug: Cladribine;   Drug: Cytarabine;   Biological: Granulocyte Colony-Stimulating Factor;   Drug: Mitoxantrone;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Jazz Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Adult Diffuse Large Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphom a;   Lymphoblastic Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Sy...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: December 2019Source: Cytotherapy, Volume 21, Issue 12Author(s): Seshu Tyagarajan, David Schmitt, Christopher Acker, Erik RutjensAbstractTisagenlecleucel, a CD19-specific autologous chimeric antigen receptor (CAR)–T cell therapy, is efficacious for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The tisagenlecleucel manufacturing process was initially developed in an academic setting and subsequently transferred to industry for qualification, validation and scaling up for global clinical trials and commercial distribution. Use of f...
Source: Cytotherapy - Category: Cytology Source Type: research
Thumbnail images in electronic health records provide insights into the patients we care for.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Photography Electronic Health Records Computers and the Internet Chemotherapy Leukemia Doctors Source Type: news
Chronic Lymphocytic Leukaemia (CLL) is associated with immune suppression and susceptibility to infection. CD8+ T cell numbers are increased and demonstrate elevated expression of PD-1 and impaired function. The mechanisms driving these features of exhaustion are uncertain but are likely to include chronic immune recognition of tumor and/or infectious agents. We investigated the number, phenotype and function of total and virus-specific CD8+ T cells in 65 patients with CLL and 14 patients undergoing long-term ibrutinib therapy (median 21 months). Ibrutinib substantially reduced the number of both CD3+ T cells and CD8+ T ce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
New England Journal of Medicine,Volume 381, Issue 24, Page 2315-2326, December 2019.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
More News: Children | Genetics | Hospitals | Leukemia | Research | Study